Agilent Technologies, Inc. — Q2 FY2023 Form 10-Q
Reporting period: Three and six months ended April 30, 2023; comparisons are with the corresponding 2022 periods. Agilent provides instruments, software, services and consumables for life sciences, diagnostics and applied chemical markets. Financial statements are unaudited.
Financial performance
| Metric | Q2 FY2023 | Q2 FY2022 | Six months FY2023 | Six months FY2022 |
|---|---|---|---|---|
| Revenue | $1.717 billion | $1.607 billion | $3.473 billion | $3.281 billion |
| Gross margin | 53.8% | 53.6% | 54.5% | 54.0% |
| Operating income | $383 million | $360 million | $809 million | $736 million |
| Operating margin | 22.3% | 22.4% | 23.3% | 22.4% |
| Net income | $302 million | $274 million | $654 million | $557 million |
| Diluted EPS | $1.02 | $0.91 | $2.20 | $1.84 |
- Q2 revenue rose 7% and six-month revenue rose 6%; foreign exchange reduced reported growth by 3 and 4 percentage points, respectively.
- Six-month operating cash flow was $694 million, up from $538 million. Investing used $181 million and financing used $407 million. Cash and cash equivalents were $1.175 billion at April 30, versus $1.053 billion at October 31, 2022.
- Current assets were $3.949 billion and current liabilities $1.666 billion. Debt was $2.733 billion, comprising $600 million of term loans and $2.133 billion of senior notes; there were no revolver or commercial-paper borrowings at period-end.
- Q2 segment revenue and year-over-year growth: Life Sciences and Applied Markets, $968 million (+8%); Diagnostics and Genomics, $362 million (+1%); Agilent CrossLab, $387 million (+10%). Diagnostics and Genomics operating income fell 20% to $73 million, while Life Sciences and Applied Markets rose 16% to $264 million and CrossLab rose 18% to $103 million.
Changes, outlook and notable items
- Growth was broad across segments and regions, with strong China demand supporting Asia Pacific. CrossLab services and Life Sciences and Applied Markets led segment growth; Diagnostics and Genomics faced softness in genomics and next-generation sequencing markets, customer purchase delays and weaker academia/government demand.
- Management cited higher sales volume, targeted pricing and lower logistics costs as gross-margin supports, partly offset by currency, wage and inventory costs. Q2 operating margin was essentially flat year over year; the six-month margin improved 1 percentage point.
- No quantified full-year revenue or earnings guidance is stated in the provided filing text. Management expects a challenging FY2023 macroeconomic environment and continuing inflation and interest-rate pressure, but remains optimistic about long-term end-market growth. Planned FY2023 capital expenditures are approximately $500 million; Agilent announced a $725 million expansion of its Frederick, Colorado nucleic-acid-therapeutics manufacturing capacity.
- Six-month operating cash flow benefited in part from deferring estimated U.S. tax payments to the fiscal fourth quarter under IRS relief for designated California counties. Inventory was $1.103 billion; inventory days on hand increased to 125 from 113 a year earlier, and days’ sales outstanding rose to 73 from 69.
- The effective tax rate was 19.9% for Q2 and 16.9% for the six months, versus 17.7% and 14.6%. Management attributed the increase primarily to mandatory capitalization of R&D expenses under a tax-law change; six-month results also included $13 million of excess share-based compensation tax benefits and $9 million from expiration of foreign statutes of limitation.
- Agilent paid $133 million in dividends and repurchased $160 million of shares during the six months. A new $2.0 billion repurchase authorization began March 1; approximately $1.939 billion remained at April 30. The board declared a $0.225-per-share quarterly dividend for payment in July.
- A $65 million contingent-consideration payment followed achievement of a Resolution Bioscience technical milestone. The filing reports no pending legal matters management believes are reasonably possible of having a material impact. It identifies macroeconomic, geopolitical, currency, supply-chain, customer-budget, regulatory, cybersecurity and tax risks. Disclosure controls were assessed as effective, with no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Whether growth and margins remain resilient if macroeconomic conditions weaken, particularly in Diagnostics and Genomics and customer-funded research markets.
- How much reported cash generation reflects the temporary timing of U.S. tax payments, and whether working-capital trends improve.
- Execution, timing, capital requirements and potential reimbursement incentives for the Frederick facility expansion, alongside the stated FY2023 capex plan.
- Future debt service and capital allocation, including share repurchases, dividends and the $600 million term loan’s 5.81% weighted-average rate and 2025 maturity.
- Potential changes in unrecognized tax benefits: management says significant changes within 12 months are reasonably possible but cannot estimate a range.